{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:05Z","timestamp":1793018105676,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis Biotherapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01918-4","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:17:45Z","timestamp":1789492665000},"page":"5793-5803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7855-8319","authenticated-orcid":false,"given":"Marley","family":"Cutrona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7781-5355","authenticated-orcid":false,"given":"Alexandra K.","family":"Golant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"8","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312.","journal-title":"JAMA Dermatol"},{"issue":"10086","key":"1918_CR2","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"11","key":"1918_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160(11):1161\u201370.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1918_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","volume":"160","author":"CM Boesjes","year":"2024","unstructured":"Boesjes CM, Kamphuis E, de Graaf M, et al. Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis. JAMA Dermatol. 2024;160(10):1044\u201355.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1918_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1918_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312\u20135.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1918_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14740338.2024.2326480","volume":"23","author":"E Camela","year":"2024","unstructured":"Camela E, Giampetruzzi AR, De Pit\u00e0 O, et al. Dupilumab in real-life settings: a review of adverse events and their pathogenesis. Expert Opin Drug Saf. 2024;23(4):439\u201347.","journal-title":"Expert Opin Drug Saf"},{"key":"1918_CR8","first-page":"1","volume":"0","author":"K Khodadad","year":"2026","unstructured":"Khodadad K, Chin NE, Chovatiya R. PDE4 inhibition in dermatologic disease: impacts beyond inflammation. Int J Dermatol. 2026;0:1\u201311.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1918_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.36849\/JDD.9089","volume":"24","author":"NT Issa","year":"2025","unstructured":"Issa NT, Obagi S, Damiani G, et al. PDE4 inhibitors: bridging molecular insights with clinical impact. J Drugs Dermatol. 2025;24(6):631\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1918_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/derm.2024.0418","volume":"37","author":"EL Simpson","year":"2026","unstructured":"Simpson EL, Eichenfield LF, Papp KA, et al. Long-term safety and efficacy with roflumilast cream 0.15% in patients aged \u2265 6 years with atopic dermatitis: a phase 3 open-label extension trial. Dermatitis. 2026;37(1):75\u201383.","journal-title":"Dermatitis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01918-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:04:01Z","timestamp":1793016241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01918-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01918-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"28 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marley Cutrona reports no conflicts of interest. Alexandra K. Golant has received consulting or speaker fees from: Abbvie, Apogee Therapeutics, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi, and Takeda Pharmaceuticals\n                      .","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Icahn School of Mount Sinai Institutional Review Board (No. 26\u201300427). Consent for the publication of patient photographs was obtained by the authors and all patients gave consent with the understanding that this information may be publicly available.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}